Eli Lilly and Company said it recently presented data related to its phase 3 study of Cyramza (ramucirumab) in treating advanced non-small cell lung cancer (NSCLC) at the 18th World Conference on Lung Cancer (WCLC), which was hosted by the International Association for the Study of Lung Cancer in Yokohama, Japan.
Results from the phase 3 trial involving Cyramza plus docetaxel are promising, the Lilly release said. The trial showed improved overall survival, progression-free survival and objective response rate for patients with NSCLC.
"Despite recent advancements, patients with aggressive, rapidly progressing advanced non-small cell lung cancer who progress before or at the time of their first scan – which is typically done between nine and 12 weeks – often have a less favorable response to their second-line therapy,” Dr. Martin Reck of the department of thoracic oncology at Lung Clinic Grosshansdorf said in the release. “This is a population that has poor prognosis and immediate unmet needs with limited treatment options.”
"This REVEL exploratory analysis demonstrated that efficacy, safety, and quality-of-life outcomes among patients receiving ramucirumab plus docetaxel who have aggressive disease with rapid progression on first-line therapy are consistent with the outcomes of the intent-to-treat population,” Reck said in the release. “These results suggest that such patients may derive meaningful benefit from ramucirumab plus docetaxel in the second-line setting."